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Abstract 
Many newly discovered drug molecules have low aqueous solubility, which results in low 
bioavailability. One way to improve their dissolution is to formulate them as nanoparticles, 
which have high specific surface areas, consequently increasing the dissolution rate and 
solubility. Nanoparticles can be produced via top-down or bottom-up methods. Top-down 
techniques such as wet milling and high pressure homogenisation involve reducing large 
particles to nano-sizes. Some pharmaceutical products made by these processes have been 
marketed. Bottom-up methods such as precipitation and controlled droplet evaporation form 
nanoparticles from molecules in solution. To minimise aggregation upon drying and promote 
redispersion of the nanoparticles upon reconstitution or administration, hydrophilic matrix 
formers are added to the formulation. However, the nanoparticles will eventually agglomerate 
together after dispersing in the liquid and hinders dissolution. Currently there is no 
pharmacopoeial method specified for nanoparticles. Amongst the current dissolution 
apparatus available for powders, the flow-through cell has been shown to be the most suitable. 
Regulatory and pharmacopoeial standards should be established in the future to standardise 
the dissolution testing of nanoparticles. More nanoparticle formulations of new hydrophobic 
drugs are expected to be developed in the future with the advancement of nanotechnology. 
However, the agglomeration problem is inherent and difficult to overcome. Thus the benefit 
of dissolution enhancement often cannot be fully realised. On the other hand, chemical 
strategies such as modifying the parent drug molecule to form a more soluble salt form, 
prodrug, or cyclodextrin complexation are well established and have been shown to be 
effective in enhancing dissolution. Thus the value of nanoformulations needs to be 
interpreted in the light of their limitations. Chemical approaches should also be considered in 
new product development. 
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Introduction 
Many new drugs discovered in recent decades are hydrophobic and poorly soluble in water. 
This poses challenges in their formulation and delivery. Improving the solubility would 
enhance bioavailability, especially if the drug concerned belongs to Class II (low solubility, 
high permeability) in the Biopharmaceutics Classification System (BCS) [1] because 
dissolution is the rate-limiting step. Lipid/organic solutions/emulsions are not always viable 
because organic solvents are toxic and the liquid volumes required for dosing may be too 
large to be practical. 
 
Drug dissolution can be improved by increasing the particle specific surface area (surface 
area-to-mass ratio) because dissolution is a surface phenomenon. Formulating drugs as 
nanoparticles is such an approach that is gaining global interest due to advancements in 
nanotechnology. Particles of sizes between a few nanometres to 1000 nm are generally 
considered as nanoparticles in the pharmaceutical field [2]. Nanoparticles are versatile and 
can be applied to any route of administration, including intravenous injection, because 
nanoparticles are sufficiently small for intracapillary passage [3]. The term ‘nanoparticle’ has 
many connotations. It has been used to refer to nanometre-sized solids, micelles, liposomes, 
and dendrimers. This review focuses on the dissolution properties and formulation aspects of 
nanometre-sized solids. Thus the term ‘nanoparticle’ is used to refer to such solids in this 
article. 
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Dissolution properties of nanoparticles 
Dissolution rate of solids in general is described quantitatively by the Nernst-Brunner 
equation: 
𝑑𝑀
𝑑𝑡
=
𝐷𝑆
𝑉ℎ
(𝐶𝑆 − 𝐶)  (Equation 1) [4]  
where M is the mass of drug dissolved in time t, dM/dt the mass dissolution rate, D the 
diffusion coefficient of the solute in solution, S the surface area of the solid drug exposed to 
the solvent, V the volume of the dissolution medium, h the diffusion layer thickness, CS the 
solubility of the drug at the solid surface, and C the solute concentration in the bulk solution 
at time t. Nanoparticles increase dissolution rate (dM/dt) by increasing two variables in the 
equation, namely, the surface area (S) and solubility (CS). These are discussed separately 
below. 
 
Surface area 
Nanoparticles have a larger surface area than that of micron-sized particles of the same 
volume. Consider the following example for the purpose of illustration. A 100 µm cube has a 
volume of 10
6
 µm
3
 and a total surface area of 6×10
4
 µm
2
. If this cube is divided into 100 nm 
cubes, the total volume remains the same but the total surface area will become 6×10
7
 µm
2
, 
which is a thousand-fold increase in surface area. In general, the surface area is increased by 
the same factor as that for size reduction. By increasing the surface area available to the 
solvent, the dissolution rate will also be increased (Equation 1). However, this effect is only 
realised if the nanoparticles are dispersed in, and fully wetted by, the solvent as discrete 
particles, which is often not the case in reality. Nanoparticles are usually very cohesive due to 
their high surface energy [5] and large specific surface area available for van der Waals 
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interaction [6]. Thus they have a high tendency to form aggregates and reduce the effective 
surface area exposed to the solvent. Nanoparticles have been observed to form random 
aggregates when exposed to the dissolution medium and displayed dissolution profiles 
suggestive of those of larger particles [7]. This confirmed that the nanoparticles behaved as 
aggregates rather than as primary particles during dissolution. Besides the problem of 
aggregation, the hydrophobicity of the nanoparticles also disfavours wetting. These are the 
challenges that need to be overcome during formulation and dissolution testing, as discussed 
in later sections. 
 
Solubility 
Solubility is also known as the saturation concentration, which is the maximum concentration 
that a compound can achieve in solution for a particular solvent. For particles of sizes in the 
micrometre range or larger, the solubility is generally independent of particle size. However, 
the solubility of nanoparticles increases with decreasing particle size [2]. This can be 
explained by the Ostwald-Freundlich equation: 
ln(
𝐶𝑠,𝑟
𝐶𝑠,∞
) =
2𝛾𝑉𝑚
𝑟𝑅𝑇
  (Equation 2) [8] 
where Cs,r and Cs,∞ are the solubilities of a drug particle with radius r and ∞ (i.e. a flat solid 
drug surface), respectively, γ is the interfacial tension between the liquid medium and the 
particle, Vm the molar volume of the drug molecule, R the universal gas constant, and T the 
absolute temperature. From the equation, it is evident that Cs,r increases with decreasing 
particle size. Therefore nanoparticles have a higher saturation concentration than their 
micron-sized counterparts. Since dM/dt is proportional to the concentration gradient (CS – C) 
(Equation 1), increasing the solubility will also increase the dissolution rate. 
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Amorphicity 
Depending on the composition and the production method and conditions, the resultant 
nanoparticles may be crystalline or amorphous (production methods are discussed in a later 
section). Amorphous solids have higher free energy, enthalpy, and entropy than the 
corresponding crystalline form [2, 9-11]. That means it is easier for amorphous drugs to go 
into solution. Consequently, they have higher dissolution rates and solubility than crystals of 
the same particle size [2, 9-11]. Therefore, from the viewpoint of dissolution enhancement, 
amorphous nanoparticles would be the ideal formulation [2]. However, this would only be 
acceptable if the nanoparticles can remain amorphous over the product shelf life because 
stability is the overriding criterion for any pharmaceutical formulation. There are hitherto no 
reported studies comparing the dissolution rates between amorphous and crystalline 
nanoparticles of the same formulation and of the same particle sizes. Particles of different 
formulations and/or different particle sizes are involved in comparison studies. Perhaps this is 
due to the difficulty in controlling all the variables except for the solid state. For instance, the 
dissolution rates of three ziprasidone formulations have been tested: 1) lyophilised 
ziprasidone mesylate-sulfobutyl ether β-cyclodextrin amorphous complex, 2) wet-milled 
ziprasidone free base nanocrystal suspension, and 3) jet-milled micron-sized ziprasidone 
hydrochloride crystals, which differ by salt form, particle size, excipient, and solid state [12]. 
 
Nanoparticle production methods 
There are two categories of nanoparticle production methods, namely, top-down and bottom-
up. Top-down techniques obtain nanoparticles through size reduction of large particles while 
bottom-up approaches form nanoparticles from assembling molecules in solution. In general, 
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top-down and bottom-up methods produce crystalline and amorphous nanoparticles, 
respectively. 
 
Top-down methods 
Large drug particles can be broken down to nano-size by wet milling or high pressure 
homogenisation. In wet milling, the particles are crushed and fragmented by milling beads 
whilst suspended in a non-solvent, which is usually water for hydrophobic drugs [13-15]. A 
stabiliser may be added to the suspension if needed to prevent nanoparticle agglomeration 
[13]. The liquid medium facilitates recrystallisation of amorphous surfaces generated during 
milling. Industrial scale wet milling (NanoCrystal
®
 Technology, Elan Pharma) has been used 
for the production of marketed pharmaceutical products, such as Rapamune
®
 
(rapamycin/sirolimus; oral tablet), Emend
®
 (aprepitant, oral spray coated capsule), TriCor
®
 
(fenofibrate; oral tablet), Megace
®
 ES (megestrol acetate; oral nanosuspension), and 
INVEGA
®
 SUSTENNA
®
 (paliperidone palmitate; injectable nanosuspension) [13]. These 
products have better bioavailability than if the drugs were formulated as large particles. More 
drugs have been successfully wet milled into nano-formulations using a variety of stabilisers. 
These have been comprehensively reviewed by Merisko-Liversidge and Liversidge [13]. 
 
High pressure homogenisation includes microfluidisation and piston-gap homogenisation. In 
microfluidisation, large particles are milled by the collision of two high pressure fluid jets 
[16]. On the other hand, piston-gap homogenisation breaks down particles by forcing a liquid 
suspension of the drug at high pressure through a narrow gap or channel inside a pipe [16, 17]. 
Bubbles form inside this gap for aqueous liquids. When the bubbles pass out from the narrow 
gap, they collapse and generate the cavitation energy that break down the particles. The 
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marketed product Triglide
®
 (fenofibrate) is made by high pressure homogenisation by 
SkyePharma [18]. 
 
Bottom-up methods 
Nanoparticles can be formed from molecules in solution by precipitation or controlled 
evaporation of droplets. Since these processes are relatively rapid (in the order of 
microseconds to a few seconds), there is very little time for the molecules to arrange into 
regular crystal lattices during particle formation. Thus bottom-up methods often produce 
amorphous nanoparticles. 
 
Precipitation 
Two modes of precipitation are possible: anti-solvent or reactive [19]. In anti-solvent 
precipitation, a drug solution is mixed with an anti-solvent to induce precipitation of the drug. 
The solvent and anti-solvent must be miscible. For hydrophobic drugs, the solution is made 
with an organic solvent (e.g. ethanol, isopropanol, acetone) and the anti-solvent was water. 
To improve the stability of the nanosuspension, excipients such as surfactants (e.g. sodium 
glycocholate, sodium dodecyl sulfate, lecithin) [20-22] or polymers (e.g. low molecular 
weight polyvinylpyrrolidone (PVP), Tween
®
 80, Poloxamer 188) [21] may be added to the 
formulation. These stabilisers control particle growth and prevent aggregation after mixing by 
adsorbing onto nanoparticle surfaces and forming steric or, if they are charged, electrostatic 
barriers [19]. Reactive precipitation follows a similar procedure to that described above 
except that precipitation is induced by a chemical reaction instead of an anti-solvent. For 
instance, an organic solution of salbutamol base is mixed with sulfuric acid to produce 
salbutamol sulfate nanoparticles [23]. 
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Nanosuspensions by precipitation are quite easy to produce. They can be made with standard 
laboratory glassware and magnetic stirring, if the materials and conditions are optimal [19]. 
However, to have better control on the precipitation kinetics and particle size distribution, 
more sophisticated techniques and apparatus are needed to achieve rapid micro-mixing [19], 
which is mixing on the molecular scale dominated by diffusion [24]. Such methods include 
high-gravity controlled precipitation (HGCP) [25-27], flash precipitation using confined 
liquid impinging jets (CLIJ) [20, 28, 29] or multi-inlet vortex mixers (MIVM) [22, 30-33], 
supercritical fluid technology [34-36], and sonoprecipitation [37]. Of these, HGCP can 
produce both amorphous [38, 39] and crystalline [23, 39-41] nanoparticles and has been 
applied in industrial scale production. 
 
Controlled droplet evaporation 
Solutes in droplets will form particles after the solvent has evaporated. If the initial droplet 
size is sufficiently small or if the solute concentration is dilute, then nanoparticles will result 
after drying. This can be achieved with a Nano Spray Dryer [42, 43], an aerosol flow reactor 
[44-48], or an electrospray [49, 50], all of which involve atomising the drug solution into an 
aerosol followed by solvent evaporation and particle collection. The drying parameters may 
affect the characteristics of the nanoparticles. There was a systematic study that investigated 
the various factors that influenced the production of spray dried bovine serum albumin 
nanoparticles [43]. The morphology and particle size were affected by the concentration of 
surfactant (Tween 80) and nozzle mesh size, respectively [43]. The inclusion of the surfactant 
produced smooth spherical particles. On the other hand, wrinkled, donut-shaped, and 
irregular particles were produced without the surfactant. This was attributed to a change in 
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the balance between surface and viscous forces of the protein solution by the surfactant [43]. 
The aerosol flow reactor offers control on the temperature history and droplet residence time 
during drying. Spherical beclomethasone dipropionate nanoparticles with a geometric mean 
diameter of 80 nm at 40°C have been produced using this method [19]. When the drying 
temperature was adjusted to 160°C, the particle size increased to 125 nm and cavities formed 
inside the particles. The faster evaporation rate at the higher temperature led to the formation 
of a solid crust at the particle surface that prevented the diffusion of solute to the interior [19]. 
The drying temperature may also influence the solid state of the resultant nanoparticles. 
Therefore, the aerosol flow reactor may be used to control the particle polymorphic form and 
morphology. 
 
Stability issues of nanoparticles 
Stability issues can be chemical or physical in nature. Nanoparticles are either dried or 
suspended in a liquid with low solubility for the drug. Therefore they are quite stable 
chemically in general. The major issue for nanoparticles is physical instability, which include 
agglomeration, Ostwald ripening, and solid state changes. 
 
Due to their large specific surface area and high surface energy, nanoparticles in liquid media 
tend to aggregate to lower the energy state of the system. This may lead to sedimentation, 
uneven dosing, and dissolution rate reduction because the exposed surface area is decreased 
[51]. Stabilisers such as surfactants (e.g. sodium dodecyl sulphate, Tween 80) and polymers 
(e.g. polyvinylpyrrolidone, Pluronics
®
) may be added to the formulation to improve the 
stability of nanosuspensions. A comprehensive list of stabilisers is available in the literature 
[51, 52]. The stabilisers adsorb onto the surface of the nanoparticles and provide steric and/or 
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electrostatic barriers to keep the nanoparticles apart, hence stabilising the nanosuspension. 
Ions in the liquid medium form an electric double layer on the surface of the nanoparticles in 
suspension because particle surfaces are charged [51]. The electric potential at the outer layer 
is called the zeta potential and is an important indicator of the physical stability of the 
nanosuspension. The zeta potential should be about ±30 mV minimum if the nanosuspension 
is to be stabilised by electrostatic repulsion only [53]. If the stabilisation is to be maintained 
by both steric and electrostatic means then ±20 mV is adequate [53]. 
 
Ostwald ripening occurs due to the differential solubility between particles of different sizes. 
The smaller the particle, the higher is its solubility (Equation 2). If the drug is sufficiently 
soluble in the liquid, it can gradually dissolve from the smaller particles and come out of 
solution on the larger particles. Consequently there would be a net increase in particle sizes. 
A narrow size distribution will minimise Ostwald ripening [54]. If the drug is hydrophobic 
and the nanosuspension was produced by anti-solvent precipitation, the residual solvent 
content can be removed to lower the solubilising capacity of the liquid. Hence Ostwald 
ripening can be minimised [54]. Stabilisers adsorbed on the surface of the nanoparticles also 
decreases mass transfer that leads to particle growth [55]. 
 
As mentioned above, top-down techniques may introduce amorphous regions on the milled 
particles. On the other hand, amorphous particles are often produced from bottom-up 
processes. Amorphous materials have a higher energy state than their crystalline counterparts. 
Thus they would change into the crystalline form under favourable conditions, such as 
temperature, humidity, and other ingredients in the formulation. The presence of crystalline 
particles can also induce the crystallisation of amorphous material [56]. However, amorphous 
hydrocortisone and all-trans retinoic acid nanosuspensions made by precipitation have been 
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found to be stable after storage at room temperature for 3 months and refrigerated for 6 
months, respectively [57, 58]. Besides the crystallisation of amorphous solids, crystalline 
nanoparticles may undergo polymorphic changes. Nanosuspensions were made from two 
crystal forms of diclofenac (DCF1 and DCF2) by high pressure homogenisation [59]. It was 
found that this top-down technique transformed DCF2 to DCF1 in the resultant 
nanosuspensions, while the original DCF1 remained the same form as nanoparticles. 
 
Formulation strategies for enhancing nanoparticle dissolution 
Although a couple of nanoparticle formulations are marketed as suspensions (Megace ES and 
INVEGA SUSTENA), all the others are oral tablets (Rapamune and TriCor) or capsules 
(Emend). For patient compliance and ease of storage and handling, solid dosage forms are 
desired whenever possible. It may also be preferable to formulate some parenteral products as 
dry powders for reconstitution because stability is generally better in the solid state. After the 
nanoparticles are produced by a wet method (e.g. wet milling or precipitation), the 
nanosuspension would need to be dried before processing into usable solid dosage forms. 
Possible drying methods include spray drying [22, 60, 61], freeze drying [62, 63], spray 
freeze drying [64-66], and fluid bed granulation [67]. The nanoparticles would very likely be 
agglomerated after drying. That is very difficult to avoid. The important requirement is that 
the dried nanoparticles can redisperse readily and fully when they come into contact with 
water [7, 68, 69]. If they remain aggregated in liquid then the maximal surface area is not 
regained. This obviously defies the original aim of formulating them as nanoparticles for 
dissolution enhancement. 
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Redispersion of hydrophobic nanoparticles in water is particularly difficult due to their 
nonpolar nature [61]. Thus hydrophilic excipients are often added to nanosuspensions to 
minimise agglomeration of the nanoparticles upon drying and aid their future redispersion [13, 
19, 21, 69]. These excipients form a matrix in which the nanoparticles are embedded after 
drying, hence they are called ‘matrix formers’. Examples of conventional matrix formers 
include sugars (e.g. lactose, sucrose), polyols (e.g. mannitol, sorbitol), and hydrophilic 
polymers (e.g. high molecular weight polyethylene glycol (PEG), polyvinyl alcohol (PVA), 
PVP) [54, 69, 70]. Some excipients that are normally used in tablet and capsule formulations 
have been tested as non-traditional matrix formers (e.g. anhydrous dicalcium phosphate, 
microcrystalline cellulose, colloidal silicon dioxide, Inutec
®
SP1 (a polymeric surfactant 
modified from inulin) [18, 69]. The hydrophilic matrix enhances the wetting, redispersion, 
and dissolution of the nanoparticles by drawing water into the aggregates. Surfactants added 
for stabilising the nanosuspension would also facilitate wetting [13]. It has been shown that 
the dissolution of cyclosporine A nanoparticles was enhanced by co-spray drying with 
increasing amounts of mannitol as the matrix former [22]. Although the various types of 
matrix formers share the same mechanism of action, their actual performance may depend on 
other formulation factor [69]. Sucrose was found to improve the dissolution of loviride 
nanocrystals after freeze drying but it did the opposite with itraconazole [18, 71]. It was also 
observed that if too much sucrose was added, agglomeration became more prominent in the 
final phase of freeze drying [18]. On the contrary, higher amounts of microcrystalline 
cellulose increased dissolution of lyophilised itraconazole nanocrytals [18]. Of these non-
traditional matrix formers listed above, microcrystalline cellulose and Inutec SP1 showed the 
best redispersion effects with itraconazole [18, 69]. The effects of mannitol and PVA on the 
redispersion of spray freeze dried polycaprolactone (PCL) nanoparticles have been 
investigated [64]. After spray freeze drying, the PCL nanoparticles were distributed 
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throughout the porous mannitol matrix. On the other hand, although PVA coated the surface 
of the compact nanoparticle agglomerates but achieved better redispersion in water than 
mannitol [64]. The aforementioned examples illustrate that the type and amount of matrix 
former used should be considered on a case-by-case basis. A list of various drug-matrix 
former combinations reported in the literature is available in a review by Van Eerdenbrugh et 
al [52]. It is possible to produce a solid dosage form from dried nanoparticles that has the 
same bioavailability as the corresponding nanosuspension by optimising the type and 
proportion of excipients [13]. 
 
Dissolution improvement of herbal medicines using nanoparticles 
Besides enhancing the dissolution of synthetic drugs, nanotechnology has also been applied 
to hydrophobic therapeutic compounds derived from medicinal herbs, such as curcumin, 
artemisinin, camptothecin, and berberine. Thus formulating them as nanoparticles may 
improve their solubility and bioavailability. 
 
Curcumin is a polyphenol from turmeric rhizomes (Curcuma longa) and has anti-
inflammatory, antioxidant, and anticancer properties. Curcumin-loaded poly(lactic-coglycolic 
acid) (PLGA) nanoparticles had been produced by first adding raw curcumin to a 
PLGA/chloroform solution under ultrasonication [72]. Then this mixture was added to a 2% 
PVA aqueous solution/ethanol mixture, also under ultrasonication, to produce the 
nanosuspension. This suspension was centrifuged to remove the solvents and replaced with 
deionised water, followed by lyophilisation. The mean diameter of the spherical curcumin 
particles was 45 nm, with an encapsulation efficiency of approximately 91% [72]. They were 
found to reduce the viability of several prostate cancer cell lines more significantly than the 
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raw drug [72]. Another curcumin nanoparticle formulation was prepared by anti-solvent 
precipitation, followed by organic solvent removal by rotary evaporation [73]. The mean 
diameter of the resultant amorphous particles was approximately 143 nm. The dissolution 
profile of these nanoparticles in aqueous medium was significantly better than that of the raw 
micron-sized drug, with > 99% and < 1% curcumin released after 60 minutes, respectively 
[73]. 
 
Artemisinin is an anti-malarial isolated from the Chinese herb, Artemisia annua (qing hao), 
and has also been identified to possess anticancer properties [74]. Nanoparticles with mean 
diameters of about 800 nm of this compound had been produced by spray drying an ethanol 
solution. These particles showed fast dissolution, with > 90% artemisinin released in 2.5 
minutes [74]. The dissolution rate could be controlled for sustained release by coating the 
nanoparticles with various layers of oppositely charged polymers such as alginate, chitosan, 
and gelatin [74]. 
 
Camptothecin is an alkaloid from Camptotheca acuminate, is another anticancer compound. 
It had been formulated with a modified glycol chitosan–5β-cholanic acid conjugate, which 
acted as the carrier [75]. Camptothecin was mixed the carrier polymer in dimethyl sulfoxide 
(DMSO), followed by dialysis, centrifugation, and lyophilisation to obtain the nanoparticles. 
The drug encapsulation efficiency was > 80%, with mean particle diameters of about 280 nm 
[75]. The anticancer activity of the nanoparticles was compared to that of raw camptothecin 
dissolved in 10% DMSO/phosphate buffered saline on tumour-bearing mice by intravenous 
injection. The nano-formulation reduced the tumour volume more significantly than the raw 
drug solution when both were administered at 30 mg camptothecin/kg [75]. 
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Berberine is an alkaloid found in a variety of plants, mainly from the Berberis species but 
also from the Chinese herbs Phellodendron amurense (huang bo) and Coptis chinensis 
(huang lian) [76]. This compound has been shown to have many therapeutic properties, 
including antimicrobial, antihypertensive, antidiabetic, anti-hypercholesterolaemia, 
antidepressant, and anticancer, amongst others [76]. Berberine-chitosan nanoparticles had 
been prepared by anti-solvent precipitation [77]. The particles were spheroidal, with a mean 
diameter of 268 nm and an encapsulation ratio of about 65%. The in vitro berberine release 
rate in saline in 6 and 24 hours was 56.8% and 65.6%, respectively [77]. The release rate was 
higher in artificial gastric juice, which was acidic, at 85.1% in 24 hours [77]. 
 
Dissolution testing of nanoparticles 
During product development, it is imperative to measure the dissolution of a formulation to 
assess its performance. To serve this purpose, the testing method must be able to determine 
dissolution behaviour accurately. It has been shown for micon-sized hydrophobic particles 
that wetting worsens with decreasing particle size [78]. This problem is even more significant 
for nanoparticles, especially if they are in powder form, so it is important to employ a suitable 
method for their dissolution measurement. 
 
Current dissolution equipments for pharmaceutical powders include the paddle, basket, flow-
through cell, and dialysis bag [68]. Except for the dialysis bag, the other three are official 
apparatus of the British and United States Pharmacopoeias (BP and USP) but they are not 
specified for nanoparticles [79, 80]. Until recently, the methods have been used on 
nanoparticle formulations by researchers with varying success due to a lack of comprehensive 
assessment on their suitability for nanoparticles [68]. Using nanoparticles of cefuroxime 
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axetil, a BCS Class II compound, as a model drug, Heng et al [68] compared the 
effectiveness of the four dissolution apparatus. Only the flow-through cell could determine 
the dissolution profile of the nanoparticles properly and reproducibly [68]. This was 
corroborated by the fact that the flow-through cell is recommended in the current edition of 
the BP for lipophilic solid dosage forms [79] and its effectiveness for these formulations had 
been demonstrated in previous studies [81, 82]. In this setup the powder is held on a plane 
inside the cell and is exposed to a constant flux of dissolution medium [68]. This minimises 
potential problems due to poor wetting and powder floatation. The discriminating power of 
the apparatus is higher at low flow rates [83]. The dissolution profile could not be accurately 
measured by the other three apparatus [68]. The paddle method showed poor wetting and 
high variability because the powder floated on the surface of the dissolution medium [68]. In 
the basket method, although the powder was initially forced to submerge into the dissolution 
medium, the powder floated and aggregated together afterwards inside the basket [68]. This 
also resulted in high variability in the data. The paddle and basket methods had been shown 
to generate non-uniform convections in the dissolution medium and introduce errors in the 
measurements [84, 85]. The dialysis bag acted as a barrier to dissolution, even though the 
molecular cutoff size was 12–14 kDa [68]. The low drug level detected in the bulk 
dissolution medium indicated that drug diffusion from the dialysis membrane was the rate-
limiting step and caused an artefact in the measurement. 
 
After the suitability of the flow-through cell was established for nanoparticles, the apparatus 
has been successfully employed to differentiate the dissolution profiles of cyclosporine A 
nano-matrix formulations containing various amounts of mannitol as the hydrophilic matrix 
former [22]. However, even when the flow-through cell is used, a small amount of surfactant 
(e.g. 0.1% w/v sodium dodecyl sulfate[68], 0.25% w/v Myrj [22]) may be required in the 
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dissolution medium to facilitate wetting. The surfactant concentration cannot be too high 
because it will introduce artefacts by enhancing dissolution, especially if it is higher than the 
critical micelle concentration [86]. 
 
Theoretical versus actual dissolution behaviour 
The primary aim of formulating hydrophobic drugs into nanoparticles is to increase their 
dissolution and ultimately, their bioavailability. The advantage of nanoparticles can only be 
fully utilised if they are completely dispersed so that all of the available surface area is 
exposed. Since the surface area is increased by the same factor as that for size reduction (see 
above) and the dissolution rate is directly proportional to the surface area (Equation 1), 
therefore the dissolution rate is increased by the same factor as that for size reduction. Indeed, 
this has been demonstrated in the dissolution of nanoparticles in suspension that had not 
undergone drying [55]. The dissolution rate of megestrol acetate and griseofulvin 
nanosuspensions produced by supercritical fluid extraction of emulsions was found to be 
five- to ten-fold higher than their jet-milled, micron-sized counterparts [55]. The volume-
weighted diameters of megesterol acetate and griseofulvin nano- and micro-particles being 
compared were 254 vs 2900 nm and 760 and 5900 nm, respectively. The factor of size 
reduction for both drugs falls within the range of increase in the dissolution rate (Figure 1). 
Through mathematical modelling, the main determinants of the dissolution of these 
nanoparticles were identified to be the specific surface area and surface dissolution kinetics 
[55]. 
 
It must be noted that in the above study the nanoparticles remained in suspension after 
production and did not undergo drying. The nanoparticles were stabilised with lecithin, 
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Pluronics, PVA, Span 80, or Tween 80 [55]. Known volumes of the suspensions were 
introduced directly into dissolution bath with constant stirring. The nanoparticles could 
remain well-suspended under these favourable circumstances thus their dissolution 
conformed to theory. However, ideal dissolution behaviour of nano-formulations is rarely 
encountered because nanoparticles agglomerate easily, especially if they have been dried [7, 
87, 88]. Sager et al [87] reported the difficulty and variability in dispersing carbon black and 
titanium dioxide nanoparticles in biological fluids such as phosphate buffered saline and 
murine bronchoalveolar lavage fluid. Micron-sized agglomerates were observed by optical 
and electron microscopy. Consequently the effective surface area exposed to the liquid media 
was reduced. 
 
Agglomeration and even fusion of pure drug nanoparticles often occur upon the drying of 
nanosuspensions. Interparticulate fusion was observed in the scanning electron micrographs 
of lyophilised diclofenac nanoparticles produced by high pressure homogenisation [59] and 
the vacuum-dried cefuroxime axetil nanoparticles made by anti-solvent precipitation [7]. The 
300 nm cefuroxime axetil nanoparticles were ‘interconnected by many bridges’, akin to the 
shape of peanuts [7]. The dissolution behaviour of the dried powder was found to consist of 
two stages. The bridges between the primary nanoparticles dissolved first and released the 
individual particles [7]. Then the nanoparticles formed random agglomerates in the liquid and 
continued the dissolution in this configuration. This was supported by the observation that the 
dissolution rate could be increased by dispersing the agglomerates using ultrasonication [7]. 
Although the tabletting of nanoparticle powders may worsen the dispersion due to the extra 
interparticulate bonding former under high pressure, loading the powder into a capsule only 
slightly improved the dissolution rate over tableting [88]. This indicates that the aggregation 
of the nanoparticles in the liquid is the rate-limiting factor. Increasing the amount of 
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surfactant in the formulation can partially increase drug release [88] but it will not eliminate 
the problem altogether. Due to the potential toxicity and adverse effects on the 
physicochemical properties of the formulation, there are limits to the amount of surfactant 
that can be incorporated. Therefore, despite the significant effort that has been devoted to 
developing nano-formulations, it may not be suitable for all hydrophobic drugs, especially if 
aggregation is a major problem. The solubility issue in these cases may be better solved by 
using other strategies. 
 
Other dissolution enhancement techniques 
Increasing the surface area of drug particles by size reduction is a physical approach to 
improve dissolution. On the other hand, chemical techniques involving molecular 
transformation or interactions may also be used for that purpose. Examples of these include 
the applications of soluble salt forms, prodrugs, and cyclodextrin complexes. Micelles and 
liposomes have also been used to enhance dissolution. However, they are only limited in wet 
formulations (i.e. emulsions). It is very challenging to dry micelles and liposomes without 
damaging them. On the other hand, the other three modalities enumerated above can be easily 
produced as solids, which is precisely the state that requires dissolution enhancement the 
most. Therefore they are examined in turn below. 
 
More soluble salt forms of an otherwise poorly soluble drug have long been employed in 
pharmaceutical formulations. Since the solubility of a compound depends largely on its 
chemical structure, the salt forms are the best candidates for achieving better dissolution. The 
improvement in the solubility of an organic molecule may be enhanced more significantly by 
an ionised functional group than by any other single method [89]. For instance, the aqueous 
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solubility of naproxen base, naproxen sodium, and naproxen choline at 25°C is 0.07, 266, and 
472 mg/mL, respectively [89]. This improvement in solubility of four orders of magnitude is 
very difficult to achieve by simply formulating the drug as nanoparticles. In general, the 
pharmacology of the various salt forms of a given drug should not differ [89]. However, the 
physicochemical properties of the salt forms are expected to be different. This results in 
differences not only in their solubility, but also their dissolution rate [89]. Thus their 
pharmacokinetics and pharmacodynamics would also differ. Besides their influence on 
clinical effects, differences in physicochemical properties (e.g. density, melting point, 
hygroscopicity, stability, polymorphism, compactability etc) would also affect formulation 
and manufacturing [89-91]. Selection methods of the optimal salt form for drugs have been 
reported in the literature [90, 91]. 
 
Prodrugs have also been used in the pharmaceutical industry for many years. These are 
modified compounds that have an inert promoiety covalently bonded to the drug molecule to 
render preferred physicochemical properties. The promoiety is subsequently removed by 
enzymatic and chemical processes inside the body to regenerate the parent drug to exert 
therapeutic actions. The promoiety is typically joined to the parent molecule via a phosphate, 
ester, or peptide bond because they can be cleaved by the phosphatases, esterases, and 
peptidases in the body, respectively. The prodrug approach can increase dissolution if an 
ionisable or polar promoiety is added to a poorly soluble molecule. Many examples of 
prodrugs used for enhancing dissolution and bioavailability (e.g. fosphenytoin, sulindac 
sulfoxide, amiodarone disodium phosphate etc) are available in a comprehensive review by 
Stella and Nti-Addae [92]. Even covalently bonded lipid promoieties has been shown to 
increase water solubility of the poorly soluble phenytoin from 0.03 mg/mL of the parent 
molecule up to 2.38 mg/mL of the conjugates [93]. Obviously, the prodrug has different 
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physicochemical properties to those of the original compound. However, unlike a salt form, 
the prodrug is supposed to be inactive until after bioconversion. Thus the timing of the 
removal of the promoiety with respect to dose administration is very important as it can affect 
the pharmacokinetics and pharmacodynamics [94]. The location and kinetics of the 
bioconversion process will affect the therapeutic outcome. Any unwanted adverse effects of 
the supposedly inert prodrug should be considered too. Nevertheless, the prodrug approach is 
worthwhile for improving solubility because small chemical modifications can yield marked 
changes in the physicochemical properties [93]. 
 
Poorly soluble drugs have been formulated with cyclodextrins (CDs) to form aqueous soluble 
complexes. The pharmaceutically relevant cyclodextrins are α-, β-, and γ-CDs, which are 
naturally occurring cyclic oligosaccharides consisting of six, seven, and eight glucose units, 
respectively. The CD molecules are ring-shaped, with a hydrophilic outer surface and a 
hydrophobic cavity. Thus lipophilic drug molecules can interact with the cavity and form a 
complex with the CDs. These CDs have long been used in medications and foods [95]. 
However, of these three CDs, β-CD has the lowest water solubility (18.5 mg/mL) and 
parenteral toxicity so it has only been used in a limited number of oral and topical products 
[96]. Thus other CD derivatives with covalently bonded substituted groups have been devised 
to modify the physicochemical properties and molecular structure of the CDs [95-97]. A list 
of these derivatives and marketed products that contain them are available in the reviews by 
Stella and He [95] and Loftsson et al [96], respectively. The kinetics of complexation has 
been covered in these reviews so it will not be discussed here. Despite the usefulness of CDs, 
there are some disadvantages with the technique [97]. The drug molecule must be of a certain 
size and geometry able to interact with the confined hydrophobic cavity of the CD. There 
may also be potential issues with toxicity, regulation, and quality control of the CDs, 
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especially the synthetic ones with substituted groups. However, since several substituted CDs 
have been approved for some marketed products [96] and the formulation technique is well 
established, CD complexation is a viable method for dissolution enhancement. 
 
The major difference between the chemical approaches (salt forms, prodrugs, and CD 
complexes) and physical approach (nanoparticles) in improving dissolution is that the former 
manipulates the physicochemical properties of the drug molecule, which are the major 
determinants of solubility, rather than simply increasing the particle surface area. Besides, 
nanoparticles always will have the problem of aggregation in liquid, which is difficult to 
overcome even though initially the nanoparticles may be dispersed as individual particles.  
More importantly, the chemical approaches have had a much longer history of applications 
than the relatively new field of nanotechnology. The knowledge and experience in the use of 
salt forms, prodrugs, and CD complexes gained over the past decades are transferrable to new 
drugs with low solubility. Therefore, the value of nanoparticles in dissolution enhancement 
may have been overestimated. Undoubtedly, nanoparticles can facilitate dissolution but the 
actual improvement is often lower than that expected in theory. More importantly, the 
chemical approaches can potentially excel the nanoparticles in that regard. It is thus advisable 
to have a realistic view of the value of nanoparticles and keep a broad perspective on the 
usefulness of other strategies in enhancing drug dissolution. 
 
Conclusion 
Nanoparticles have been advocated in recent years for their effectiveness in enhancing 
dissolution, bioavailability, and convenience in administration. With an increasing number of 
hydrophobic drugs discovered and advancement in nanotechnology, much effort and 
25 
resources have been spent on developing nanoformulations. Although wet milling appears to 
be the main method of commercial nanoparticle production (owing to the number of 
approved products already and more still in the pipeline), there are other directions that are 
worth exploring. 
 
Firstly, with the growing prominence and number of nanoparticle formulations, official 
pharmacopoeial and regulatory guidelines should be devised for the dissolution testing of 
nanoparticles. Although the effectiveness of the various dissolution apparatus has been 
compared in a recent research article [68], there is still no definitive standard for the 
procedure. Formulators are still free to select and adapt a setup to suit their own purpose. 
Since each method has its own problems, data generated from different apparatus may not be 
comparable. Even the flow-through cell cannot entirely eliminate aggregation during 
dissolution testing [7]. Thus there is a need to reach a consensus on one or a set of apparatus 
and methods that can accurately measure the dissolution of nanoparticles. If the existing 
official pharmacopoeial apparatus do not satisfy this end, then they may require modification 
or an entirely new device may need to be developed. That was how the Next Generation 
Impactor (BP Apparatus E and USP Apparatus 5 for aerosol testing) [79, 80] came to be 
specifically designed to fulfil the requirements that were not met by older generation 
pharmacopoeial impactors [98]. The establishment of standards for dissolution testing of 
nanoparticles will definitely have a vast positive impact on the research and development of 
nano-formulations. 
 
Secondly, despite the high interest in nanotechnology nowadays, researchers should be 
conscious of the inherent shortcomings of nanoformulations. The agglomeration of 
nanoparticles limits the exposed surface area, and hence the effectiveness of dissolution 
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enhancement by size reduction. Moreover, small chemical modifications to the parent 
molecule (e.g. transformation to a more soluble salt form, prodrug, or CD complex) can 
increase solubility more significantly than by nano-sizing. Therefore, although 
nanoformulations do possess some benefits in enhancing drug dissolution, their value and 
cost effectiveness should be viewed in the light of their limitations. The more established 
chemical approaches may also be considered in the formulation of future products. A 
summary of the points examined in this review is summarised in Table 1. 
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Table 1. Summary of aspects of nano-formulations and other techniques for dissolution enhancement. 
Nanoparticle production 
methods 
Top-down  Wet milling; Approved products: Triglide (fenofibrate)17 
 High pressure homogenization; Approved products: Rapamune 
(rapamycin/sirolimus), Emend (aprepitant), TriCor (fenofibrate), Megace ES 
(megestrol acetate), INVEGA SUSTENNA (paliperidone palmitate)12 
Bottom-up  Precipitation: Standard laboratory apparatus, HGCP, CLIJ, MIVM, supercritical 
fluid, sonoprecipitation19, 21, 24-40 
 Controlled droplet evaporation: Nano Spray Dryer, aerosol flow reactor, 
electrospray41-49 
Formulation strategies for 
nanoparticle dissolution 
enhancement 
Drying of 
nanosuspensions 
 Spray drying, freeze drying, spray freeze drying, fluid bed granulation21, 59-66 
Incorporation of 
hydrophilic 
matrix formers 
 Conventional: sugars (lactose, sucrose), polyols (mannitol, sorbitol), polymers (high 
molecular weight PEG, PVA, PVP)53, 68, 69 
 Non-traditional: anhydrous dicalcium phosphate, microcrystalline cellulose, 
colloidal silicon dioxide, Inutec®SP117, 68 
Dissolution testing of 
nanoparticles 
  Pharmacopoeial (BP and USP): Paddle, basket, flow-through cell67 
 Dialysis bag67 
Note: No official dissolution method is specified for nanoparticles hitherto. The flow-
through cell has been shown to be the most suitable67 
Theoretical versus actual 
dissolution behaviour 
  Ideal case: The factor of increase in the dissolution rate of megesterol acetate and 
griseofulvin nano- and micro-suspensions (254 vs 2900 nm and 760 and 5900 nm, 
respectively) was comparable to that of size reduction54 
 Usual case: Nanoparticles agglomerate easily, especially after drying7, 80, 81, 
sometimes even interparticulate fusion occurs7, 58 
 Two stages of nanoparticle dissolution: 1) Interparticulate bridges dissolve and 
primary nanoparticles are released; and 2) Nanoparticles form aggregates and 
continue the dissolution in this manner7 
33 
Other dissolution 
enhancement techniques 
Chemical 
approaches 
 Soluble salt forms: E.g. solubility of naproxen base (0.07 mg/mL) could be 
increased to 266 and 472 mg/mL by using naproxen sodium and naproxen choline, 
respectively82 
 Prodrugs: E.g. solubility of phenytoin (0.03 mg/mL) could be increased up to 2.38 
mg/mL by adding a covalently-bonded promoiety to the parent molecule86 
 Cyclodextrin complexes: many marketed products using α-, β-, and γ-cyclodextrin 
and their substituted counterparts88,89 
Future directions 
  Establishment of regulatory and pharmacopoeial standards for dissolution testing of 
nanoparticles 
 Besides nano-sizing, chemical approaches for dissolution enhancement should also 
be considered in product development 
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Figure 1. Dissolution profiles of megesterol acetate and griseofulvin nano- and micro-particles. Data adapted from Reference [55]. 
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